A switch from GnRH agonist to GnRH antagonist in castration-resistant prostate cancer patients leads to a low response rate on PSA

No abstract is available for this paper.

• Publication year

  2013

• Venue

  World journal of urology

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00345-012-0841-1PMID 22527669
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.

  2011cited by this paper
• Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer

  2011cited by this paper
• Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence.

  2011cited by this paper
• A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

  2011cited by this paper
• Expression of follicle-stimulating hormone receptor in tumor blood vessels.

  2010cited by this paper
• Secondary hormonal therapy for advanced prostate cancer.

  2006cited by this paper
• Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.

  1999cited by this paper

• Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer

  2021cites this paper
• Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions

  2020cites this paper
• Switching from a GnRH agonist to a GnRH antagonist in prostate cancer patients: A systematic review and meta-analysis.

  2019cites this paper
• Switching of GnRH Agent from Agonist to Antagonist in Patients with Castration-Resistant Prostate Cancer

  2016influential citation
• Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl

  2016cites this paper
• Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer.

  2016cites this paper
• Efficacy of treatment with a GnRH antagonist in prostate cancer patients previously treated with a GnRH agonist

  2015cites this paper
• Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.

  2014cites this paper
• Targeting hormonal signaling pathways in castration resistant prostate cancer.

  2014cites this paper
• [Influence of plasmatic testosterone during natural history of prostate cancer: a review].

  2013cites this paper
• Testosterone Measurement and Prostate Cancer

  2013cites this paper
• An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist

  2013cites this paper
• Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies.

  2013cites this paper
• Response to Degarelix After Resistance to Leuprolide in a Patient With Metastatic Prostate Cancer

  2012cites this paper